Recruiting
Phase 1

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT04201873

Conditions

Recurrent Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dendritic Cell Tumor Cell Lysate Vaccine

Pembrolizumab

Placebo Administration

Poly ICLC

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information